The Cooper Companies, Inc.
The Cooper Companies, Inc. COO Peers
See (COO) competitors and their performances in Stock Market.
Peer Comparison Table: Medical - Instruments & Supplies Industry
Detailed financial metrics including price, market cap, P/E ratio, and more.
| Symbol | Price | Change % | Market Cap | P/E Ratio | EPS | Dividend Yield |
|---|---|---|---|---|---|---|
| COO | $71.18 | +5.58% | 14.2B | 34.39 | $2.07 | N/A |
| ISRG | $558.21 | +0.05% | 200.1B | 81.97 | $6.81 | N/A |
| BDXA | $59.24 | -2.24% | 49.1B | 21.44 | $2.76 | +2.32% |
| BDX | $171.01 | +0.04% | 49B | 33.21 | $5.15 | +2.32% |
| ALC | $86.94 | +1.16% | 43B | 38.64 | $2.25 | +0.38% |
| RMD | $249.73 | -0.08% | 36.6B | 28.00 | $8.92 | +0.85% |
| WST | $218.56 | +3.37% | 15.7B | 34.36 | $6.36 | +0.38% |
| BAX | $30.15 | +0.58% | 15.5B | -57.97 | -$0.52 | +2.64% |
| HOLX | $63.07 | +0.80% | 14.1B | 26.50 | $2.38 | N/A |
| BDXB | $48.16 | +1.39% | 13.7B | 7.60 | $6.33 | +2.32% |
Stock Comparison
COO vs ISRG Comparison
COO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, COO stands at 14.2B. In comparison, ISRG has a market cap of 200.1B. Regarding current trading prices, COO is priced at $71.18, while ISRG trades at $558.21.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
COO currently has a P/E ratio of 34.39, whereas ISRG's P/E ratio is 81.97. In terms of profitability, COO's ROE is +0.05%, compared to ISRG's ROE of +0.16%. Regarding short-term risk, COO is more volatile compared to ISRG. This indicates potentially higher risk in terms of short-term price fluctuations for COO.
COO vs BDXA Comparison
COO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, COO stands at 14.2B. In comparison, BDXA has a market cap of 49.1B. Regarding current trading prices, COO is priced at $71.18, while BDXA trades at $59.24.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
COO currently has a P/E ratio of 34.39, whereas BDXA's P/E ratio is 21.44. In terms of profitability, COO's ROE is +0.05%, compared to BDXA's ROE of +0.06%. Regarding short-term risk, COO is less volatile compared to BDXA. This indicates potentially lower risk in terms of short-term price fluctuations for COO.
COO vs BDX Comparison
COO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, COO stands at 14.2B. In comparison, BDX has a market cap of 49B. Regarding current trading prices, COO is priced at $71.18, while BDX trades at $171.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
COO currently has a P/E ratio of 34.39, whereas BDX's P/E ratio is 33.21. In terms of profitability, COO's ROE is +0.05%, compared to BDX's ROE of +0.06%. Regarding short-term risk, COO is more volatile compared to BDX. This indicates potentially higher risk in terms of short-term price fluctuations for COO.
COO vs ALC Comparison
COO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, COO stands at 14.2B. In comparison, ALC has a market cap of 43B. Regarding current trading prices, COO is priced at $71.18, while ALC trades at $86.94.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
COO currently has a P/E ratio of 34.39, whereas ALC's P/E ratio is 38.64. In terms of profitability, COO's ROE is +0.05%, compared to ALC's ROE of +0.07%. Regarding short-term risk, COO is more volatile compared to ALC. This indicates potentially higher risk in terms of short-term price fluctuations for COO.
COO vs RMD Comparison
COO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, COO stands at 14.2B. In comparison, RMD has a market cap of 36.6B. Regarding current trading prices, COO is priced at $71.18, while RMD trades at $249.73.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
COO currently has a P/E ratio of 34.39, whereas RMD's P/E ratio is 28.00. In terms of profitability, COO's ROE is +0.05%, compared to RMD's ROE of +0.25%. Regarding short-term risk, COO is more volatile compared to RMD. This indicates potentially higher risk in terms of short-term price fluctuations for COO.
COO vs WST Comparison
COO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, COO stands at 14.2B. In comparison, WST has a market cap of 15.7B. Regarding current trading prices, COO is priced at $71.18, while WST trades at $218.56.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
COO currently has a P/E ratio of 34.39, whereas WST's P/E ratio is 34.36. In terms of profitability, COO's ROE is +0.05%, compared to WST's ROE of +0.17%. Regarding short-term risk, COO is more volatile compared to WST. This indicates potentially higher risk in terms of short-term price fluctuations for COO.
COO vs BAX Comparison
COO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, COO stands at 14.2B. In comparison, BAX has a market cap of 15.5B. Regarding current trading prices, COO is priced at $71.18, while BAX trades at $30.15.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
COO currently has a P/E ratio of 34.39, whereas BAX's P/E ratio is -57.97. In terms of profitability, COO's ROE is +0.05%, compared to BAX's ROE of -0.08%. Regarding short-term risk, COO is more volatile compared to BAX. This indicates potentially higher risk in terms of short-term price fluctuations for COO.
COO vs HOLX Comparison
COO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, COO stands at 14.2B. In comparison, HOLX has a market cap of 14.1B. Regarding current trading prices, COO is priced at $71.18, while HOLX trades at $63.07.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
COO currently has a P/E ratio of 34.39, whereas HOLX's P/E ratio is 26.50. In terms of profitability, COO's ROE is +0.05%, compared to HOLX's ROE of +0.11%. Regarding short-term risk, COO is more volatile compared to HOLX. This indicates potentially higher risk in terms of short-term price fluctuations for COO.
COO vs BDXB Comparison
COO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, COO stands at 14.2B. In comparison, BDXB has a market cap of 13.7B. Regarding current trading prices, COO is priced at $71.18, while BDXB trades at $48.16.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
COO currently has a P/E ratio of 34.39, whereas BDXB's P/E ratio is 7.60. In terms of profitability, COO's ROE is +0.05%, compared to BDXB's ROE of +0.06%. Regarding short-term risk, COO is more volatile compared to BDXB. This indicates potentially higher risk in terms of short-term price fluctuations for COO.
COO vs ATR Comparison
COO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, COO stands at 14.2B. In comparison, ATR has a market cap of 10.1B. Regarding current trading prices, COO is priced at $71.18, while ATR trades at $152.59.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
COO currently has a P/E ratio of 34.39, whereas ATR's P/E ratio is 27.90. In terms of profitability, COO's ROE is +0.05%, compared to ATR's ROE of +0.15%. Regarding short-term risk, COO is more volatile compared to ATR. This indicates potentially higher risk in terms of short-term price fluctuations for COO.
COO vs MASI Comparison
COO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, COO stands at 14.2B. In comparison, MASI has a market cap of 8.9B. Regarding current trading prices, COO is priced at $71.18, while MASI trades at $164.79.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
COO currently has a P/E ratio of 34.39, whereas MASI's P/E ratio is -30.18. In terms of profitability, COO's ROE is +0.05%, compared to MASI's ROE of -0.41%. Regarding short-term risk, COO is more volatile compared to MASI. This indicates potentially higher risk in terms of short-term price fluctuations for COO.
COO vs RGEN Comparison
COO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, COO stands at 14.2B. In comparison, RGEN has a market cap of 7.1B. Regarding current trading prices, COO is priced at $71.18, while RGEN trades at $126.70.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
COO currently has a P/E ratio of 34.39, whereas RGEN's P/E ratio is -309.02. In terms of profitability, COO's ROE is +0.05%, compared to RGEN's ROE of -0.01%. Regarding short-term risk, COO is more volatile compared to RGEN. This indicates potentially higher risk in terms of short-term price fluctuations for COO.
COO vs STVN Comparison
COO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, COO stands at 14.2B. In comparison, STVN has a market cap of 6.3B. Regarding current trading prices, COO is priced at $71.18, while STVN trades at $23.18.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
COO currently has a P/E ratio of 34.39, whereas STVN's P/E ratio is 44.58. In terms of profitability, COO's ROE is +0.05%, compared to STVN's ROE of +0.09%. Regarding short-term risk, COO is more volatile compared to STVN. This indicates potentially higher risk in terms of short-term price fluctuations for COO.
COO vs MMSI Comparison
COO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, COO stands at 14.2B. In comparison, MMSI has a market cap of 5.6B. Regarding current trading prices, COO is priced at $71.18, while MMSI trades at $95.21.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
COO currently has a P/E ratio of 34.39, whereas MMSI's P/E ratio is 46.67. In terms of profitability, COO's ROE is +0.05%, compared to MMSI's ROE of +0.09%. Regarding short-term risk, COO is more volatile compared to MMSI. This indicates potentially higher risk in terms of short-term price fluctuations for COO.
COO vs TFX Comparison
COO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, COO stands at 14.2B. In comparison, TFX has a market cap of 5.4B. Regarding current trading prices, COO is priced at $71.18, while TFX trades at $122.44.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
COO currently has a P/E ratio of 34.39, whereas TFX's P/E ratio is 37.91. In terms of profitability, COO's ROE is +0.05%, compared to TFX's ROE of +0.03%. Regarding short-term risk, COO is more volatile compared to TFX. This indicates potentially higher risk in terms of short-term price fluctuations for COO.
COO vs BLCO Comparison
COO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, COO stands at 14.2B. In comparison, BLCO has a market cap of 4.1B. Regarding current trading prices, COO is priced at $71.18, while BLCO trades at $11.59.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
COO currently has a P/E ratio of 34.39, whereas BLCO's P/E ratio is -11.36. In terms of profitability, COO's ROE is +0.05%, compared to BLCO's ROE of -0.08%. Regarding short-term risk, COO is more volatile compared to BLCO. This indicates potentially higher risk in terms of short-term price fluctuations for COO.
COO vs HAE Comparison
COO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, COO stands at 14.2B. In comparison, HAE has a market cap of 3.4B. Regarding current trading prices, COO is priced at $71.18, while HAE trades at $70.47.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
COO currently has a P/E ratio of 34.39, whereas HAE's P/E ratio is 21.29. In terms of profitability, COO's ROE is +0.05%, compared to HAE's ROE of +0.18%. Regarding short-term risk, COO is more volatile compared to HAE. This indicates potentially higher risk in terms of short-term price fluctuations for COO.
COO vs ICUI Comparison
COO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, COO stands at 14.2B. In comparison, ICUI has a market cap of 3.3B. Regarding current trading prices, COO is priced at $71.18, while ICUI trades at $132.82.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
COO currently has a P/E ratio of 34.39, whereas ICUI's P/E ratio is -34.77. In terms of profitability, COO's ROE is +0.05%, compared to ICUI's ROE of -0.05%. Regarding short-term risk, COO is more volatile compared to ICUI. This indicates potentially higher risk in terms of short-term price fluctuations for COO.
COO vs XRAY Comparison
COO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, COO stands at 14.2B. In comparison, XRAY has a market cap of 3.2B. Regarding current trading prices, COO is priced at $71.18, while XRAY trades at $15.90.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
COO currently has a P/E ratio of 34.39, whereas XRAY's P/E ratio is -3.56. In terms of profitability, COO's ROE is +0.05%, compared to XRAY's ROE of -0.38%. Regarding short-term risk, COO is more volatile compared to XRAY. This indicates potentially higher risk in terms of short-term price fluctuations for COO.
COO vs WRBY Comparison
COO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, COO stands at 14.2B. In comparison, WRBY has a market cap of 2.6B. Regarding current trading prices, COO is priced at $71.18, while WRBY trades at $21.21.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
COO currently has a P/E ratio of 34.39, whereas WRBY's P/E ratio is -176.75. In terms of profitability, COO's ROE is +0.05%, compared to WRBY's ROE of -0.04%. Regarding short-term risk, COO is more volatile compared to WRBY. This indicates potentially higher risk in terms of short-term price fluctuations for COO.
COO vs QDEL Comparison
COO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, COO stands at 14.2B. In comparison, QDEL has a market cap of 2B. Regarding current trading prices, COO is priced at $71.18, while QDEL trades at $29.91.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
COO currently has a P/E ratio of 34.39, whereas QDEL's P/E ratio is -5.72. In terms of profitability, COO's ROE is +0.05%, compared to QDEL's ROE of -0.11%. Regarding short-term risk, COO is more volatile compared to QDEL. This indicates potentially higher risk in terms of short-term price fluctuations for COO.
COO vs LMAT Comparison
COO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, COO stands at 14.2B. In comparison, LMAT has a market cap of 1.9B. Regarding current trading prices, COO is priced at $71.18, while LMAT trades at $83.44.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
COO currently has a P/E ratio of 34.39, whereas LMAT's P/E ratio is 42.36. In terms of profitability, COO's ROE is +0.05%, compared to LMAT's ROE of +0.14%. Regarding short-term risk, COO is more volatile compared to LMAT. This indicates potentially higher risk in terms of short-term price fluctuations for COO.
COO vs NVCR Comparison
COO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, COO stands at 14.2B. In comparison, NVCR has a market cap of 1.8B. Regarding current trading prices, COO is priced at $71.18, while NVCR trades at $16.45.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
COO currently has a P/E ratio of 34.39, whereas NVCR's P/E ratio is -11.11. In terms of profitability, COO's ROE is +0.05%, compared to NVCR's ROE of -0.45%. Regarding short-term risk, COO is more volatile compared to NVCR. This indicates potentially higher risk in terms of short-term price fluctuations for COO.
COO vs ATRC Comparison
COO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, COO stands at 14.2B. In comparison, ATRC has a market cap of 1.7B. Regarding current trading prices, COO is priced at $71.18, while ATRC trades at $34.89.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
COO currently has a P/E ratio of 34.39, whereas ATRC's P/E ratio is -43.07. In terms of profitability, COO's ROE is +0.05%, compared to ATRC's ROE of -0.08%. Regarding short-term risk, COO is more volatile compared to ATRC. This indicates potentially higher risk in terms of short-term price fluctuations for COO.
COO vs AZTA Comparison
COO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, COO stands at 14.2B. In comparison, AZTA has a market cap of 1.3B. Regarding current trading prices, COO is priced at $71.18, while AZTA trades at $28.30.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
COO currently has a P/E ratio of 34.39, whereas AZTA's P/E ratio is -8.65. In terms of profitability, COO's ROE is +0.05%, compared to AZTA's ROE of -0.04%. Regarding short-term risk, COO is more volatile compared to AZTA. This indicates potentially higher risk in terms of short-term price fluctuations for COO.
COO vs PLSE Comparison
COO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, COO stands at 14.2B. In comparison, PLSE has a market cap of 1.1B. Regarding current trading prices, COO is priced at $71.18, while PLSE trades at $16.32.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
COO currently has a P/E ratio of 34.39, whereas PLSE's P/E ratio is -16.48. In terms of profitability, COO's ROE is +0.05%, compared to PLSE's ROE of -0.71%. Regarding short-term risk, COO is less volatile compared to PLSE. This indicates potentially lower risk in terms of short-term price fluctuations for COO.
COO vs KMTS Comparison
COO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, COO stands at 14.2B. In comparison, KMTS has a market cap of 1B. Regarding current trading prices, COO is priced at $71.18, while KMTS trades at $19.96.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
COO currently has a P/E ratio of 34.39, whereas KMTS's P/E ratio is -10.40. In terms of profitability, COO's ROE is +0.05%, compared to KMTS's ROE of +0.27%. Regarding short-term risk, COO is more volatile compared to KMTS. This indicates potentially higher risk in terms of short-term price fluctuations for COO.
COO vs BLFS Comparison
COO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, COO stands at 14.2B. In comparison, BLFS has a market cap of 1B. Regarding current trading prices, COO is priced at $71.18, while BLFS trades at $21.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
COO currently has a P/E ratio of 34.39, whereas BLFS's P/E ratio is -113.16. In terms of profitability, COO's ROE is +0.05%, compared to BLFS's ROE of -0.03%. Regarding short-term risk, COO is more volatile compared to BLFS. This indicates potentially higher risk in terms of short-term price fluctuations for COO.
COO vs STAA Comparison
COO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, COO stands at 14.2B. In comparison, STAA has a market cap of 861.3M. Regarding current trading prices, COO is priced at $71.18, while STAA trades at $17.39.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
COO currently has a P/E ratio of 34.39, whereas STAA's P/E ratio is -12.08. In terms of profitability, COO's ROE is +0.05%, compared to STAA's ROE of -0.18%. Regarding short-term risk, COO is less volatile compared to STAA. This indicates potentially lower risk in terms of short-term price fluctuations for COO.
COO vs ATRI Comparison
COO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, COO stands at 14.2B. In comparison, ATRI has a market cap of 809.4M. Regarding current trading prices, COO is priced at $71.18, while ATRI trades at $459.92.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
COO currently has a P/E ratio of 34.39, whereas ATRI's P/E ratio is 64.50. In terms of profitability, COO's ROE is +0.05%, compared to ATRI's ROE of +0.04%. Regarding short-term risk, COO is more volatile compared to ATRI. This indicates potentially higher risk in terms of short-term price fluctuations for COO.
COO vs ANGO Comparison
COO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, COO stands at 14.2B. In comparison, ANGO has a market cap of 445.5M. Regarding current trading prices, COO is priced at $71.18, while ANGO trades at $10.97.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
COO currently has a P/E ratio of 34.39, whereas ANGO's P/E ratio is -10.86. In terms of profitability, COO's ROE is +0.05%, compared to ANGO's ROE of -0.21%. Regarding short-term risk, COO is more volatile compared to ANGO. This indicates potentially higher risk in terms of short-term price fluctuations for COO.
COO vs NNNN Comparison
COO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, COO stands at 14.2B. In comparison, NNNN has a market cap of 361.7M. Regarding current trading prices, COO is priced at $71.18, while NNNN trades at $8.24.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
COO currently has a P/E ratio of 34.39, whereas NNNN's P/E ratio is 137.33. In terms of profitability, COO's ROE is +0.05%, compared to NNNN's ROE of +0.14%. Regarding short-term risk, COO is less volatile compared to NNNN. This indicates potentially lower risk in terms of short-term price fluctuations for COO.
COO vs NYXH Comparison
COO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, COO stands at 14.2B. In comparison, NYXH has a market cap of 290.5M. Regarding current trading prices, COO is priced at $71.18, while NYXH trades at $7.76.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
COO currently has a P/E ratio of 34.39, whereas NYXH's P/E ratio is -3.40. In terms of profitability, COO's ROE is +0.05%, compared to NYXH's ROE of -0.56%. Regarding short-term risk, COO is less volatile compared to NYXH. This indicates potentially lower risk in terms of short-term price fluctuations for COO.
COO vs SMTI Comparison
COO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, COO stands at 14.2B. In comparison, SMTI has a market cap of 256.7M. Regarding current trading prices, COO is priced at $71.18, while SMTI trades at $28.88.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
COO currently has a P/E ratio of 34.39, whereas SMTI's P/E ratio is -21.55. In terms of profitability, COO's ROE is +0.05%, compared to SMTI's ROE of -0.29%. Regarding short-term risk, COO is more volatile compared to SMTI. This indicates potentially higher risk in terms of short-term price fluctuations for COO.
COO vs OSUR Comparison
COO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, COO stands at 14.2B. In comparison, OSUR has a market cap of 210.2M. Regarding current trading prices, COO is priced at $71.18, while OSUR trades at $2.81.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
COO currently has a P/E ratio of 34.39, whereas OSUR's P/E ratio is -6.69. In terms of profitability, COO's ROE is +0.05%, compared to OSUR's ROE of -0.08%. Regarding short-term risk, COO is more volatile compared to OSUR. This indicates potentially higher risk in terms of short-term price fluctuations for COO.
COO vs STXS Comparison
COO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, COO stands at 14.2B. In comparison, STXS has a market cap of 193.3M. Regarding current trading prices, COO is priced at $71.18, while STXS trades at $2.25.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
COO currently has a P/E ratio of 34.39, whereas STXS's P/E ratio is -7.25. In terms of profitability, COO's ROE is +0.05%, compared to STXS's ROE of -2.17%. Regarding short-term risk, COO is more volatile compared to STXS. This indicates potentially higher risk in terms of short-term price fluctuations for COO.
COO vs UTMD Comparison
COO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, COO stands at 14.2B. In comparison, UTMD has a market cap of 182M. Regarding current trading prices, COO is priced at $71.18, while UTMD trades at $56.04.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
COO currently has a P/E ratio of 34.39, whereas UTMD's P/E ratio is 14.79. In terms of profitability, COO's ROE is +0.05%, compared to UTMD's ROE of +0.11%. Regarding short-term risk, COO is more volatile compared to UTMD. This indicates potentially higher risk in terms of short-term price fluctuations for COO.
COO vs ZTEK Comparison
COO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, COO stands at 14.2B. In comparison, ZTEK has a market cap of 152.3M. Regarding current trading prices, COO is priced at $71.18, while ZTEK trades at $1.46.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
COO currently has a P/E ratio of 34.39, whereas ZTEK's P/E ratio is -18.25. In terms of profitability, COO's ROE is +0.05%, compared to ZTEK's ROE of -0.58%. Regarding short-term risk, COO is more volatile compared to ZTEK. This indicates potentially higher risk in terms of short-term price fluctuations for COO.
COO vs PDEX Comparison
COO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, COO stands at 14.2B. In comparison, PDEX has a market cap of 137.7M. Regarding current trading prices, COO is priced at $71.18, while PDEX trades at $42.23.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
COO currently has a P/E ratio of 34.39, whereas PDEX's P/E ratio is 15.30. In terms of profitability, COO's ROE is +0.05%, compared to PDEX's ROE of +0.29%. Regarding short-term risk, COO is less volatile compared to PDEX. This indicates potentially lower risk in terms of short-term price fluctuations for COO.
COO vs KRMD Comparison
COO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, COO stands at 14.2B. In comparison, KRMD has a market cap of 135.7M. Regarding current trading prices, COO is priced at $71.18, while KRMD trades at $2.94.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
COO currently has a P/E ratio of 34.39, whereas KRMD's P/E ratio is -24.50. In terms of profitability, COO's ROE is +0.05%, compared to KRMD's ROE of -0.30%. Regarding short-term risk, COO is less volatile compared to KRMD. This indicates potentially lower risk in terms of short-term price fluctuations for COO.
COO vs ZJYL Comparison
COO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, COO stands at 14.2B. In comparison, ZJYL has a market cap of 124.8M. Regarding current trading prices, COO is priced at $71.18, while ZJYL trades at $0.80.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
COO currently has a P/E ratio of 34.39, whereas ZJYL's P/E ratio is 39.85. In terms of profitability, COO's ROE is +0.05%, compared to ZJYL's ROE of +0.13%. Regarding short-term risk, COO is more volatile compared to ZJYL. This indicates potentially higher risk in terms of short-term price fluctuations for COO.
COO vs INFU Comparison
COO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, COO stands at 14.2B. In comparison, INFU has a market cap of 124.7M. Regarding current trading prices, COO is priced at $71.18, while INFU trades at $5.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
COO currently has a P/E ratio of 34.39, whereas INFU's P/E ratio is 39.63. In terms of profitability, COO's ROE is +0.05%, compared to INFU's ROE of +0.08%. Regarding short-term risk, COO is more volatile compared to INFU. This indicates potentially higher risk in terms of short-term price fluctuations for COO.
COO vs MBOT Comparison
COO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, COO stands at 14.2B. In comparison, MBOT has a market cap of 97.4M. Regarding current trading prices, COO is priced at $71.18, while MBOT trades at $2.68.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
COO currently has a P/E ratio of 34.39, whereas MBOT's P/E ratio is -4.18. In terms of profitability, COO's ROE is +0.05%, compared to MBOT's ROE of -0.85%. Regarding short-term risk, COO is less volatile compared to MBOT. This indicates potentially lower risk in terms of short-term price fluctuations for COO.
COO vs MLSS Comparison
COO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, COO stands at 14.2B. In comparison, MLSS has a market cap of 70.8M. Regarding current trading prices, COO is priced at $71.18, while MLSS trades at $0.90.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
COO currently has a P/E ratio of 34.39, whereas MLSS's P/E ratio is -15.04. In terms of profitability, COO's ROE is +0.05%, compared to MLSS's ROE of -0.83%. Regarding short-term risk, COO is more volatile compared to MLSS. This indicates potentially higher risk in terms of short-term price fluctuations for COO.
COO vs AKYA Comparison
COO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, COO stands at 14.2B. In comparison, AKYA has a market cap of 56.6M. Regarding current trading prices, COO is priced at $71.18, while AKYA trades at $1.14.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
COO currently has a P/E ratio of 34.39, whereas AKYA's P/E ratio is -1.18. In terms of profitability, COO's ROE is +0.05%, compared to AKYA's ROE of -5.06%. Regarding short-term risk, COO is more volatile compared to AKYA. This indicates potentially higher risk in terms of short-term price fluctuations for COO.
COO vs OMIC Comparison
COO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, COO stands at 14.2B. In comparison, OMIC has a market cap of 50.8M. Regarding current trading prices, COO is priced at $71.18, while OMIC trades at $20.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
COO currently has a P/E ratio of 34.39, whereas OMIC's P/E ratio is -0.58. In terms of profitability, COO's ROE is +0.05%, compared to OMIC's ROE of -0.58%. Regarding short-term risk, COO is more volatile compared to OMIC. This indicates potentially higher risk in terms of short-term price fluctuations for COO.
COO vs IGAP Comparison
COO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, COO stands at 14.2B. In comparison, IGAP has a market cap of 50.2M. Regarding current trading prices, COO is priced at $71.18, while IGAP trades at $3.24.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
COO currently has a P/E ratio of 34.39, whereas IGAP's P/E ratio is -10.52. In terms of profitability, COO's ROE is +0.05%, compared to IGAP's ROE of +3.93%. Regarding short-term risk, COO is more volatile compared to IGAP. This indicates potentially higher risk in terms of short-term price fluctuations for COO.
COO vs DXR Comparison
COO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, COO stands at 14.2B. In comparison, DXR has a market cap of 42.3M. Regarding current trading prices, COO is priced at $71.18, while DXR trades at $8.75.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
COO currently has a P/E ratio of 34.39, whereas DXR's P/E ratio is -97.22. In terms of profitability, COO's ROE is +0.05%, compared to DXR's ROE of +0.02%. Regarding short-term risk, COO is less volatile compared to DXR. This indicates potentially lower risk in terms of short-term price fluctuations for COO.
COO vs NEPH Comparison
COO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, COO stands at 14.2B. In comparison, NEPH has a market cap of 36.4M. Regarding current trading prices, COO is priced at $71.18, while NEPH trades at $3.43.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
COO currently has a P/E ratio of 34.39, whereas NEPH's P/E ratio is 42.88. In terms of profitability, COO's ROE is +0.05%, compared to NEPH's ROE of +0.09%. Regarding short-term risk, COO is more volatile compared to NEPH. This indicates potentially higher risk in terms of short-term price fluctuations for COO.
COO vs POCI Comparison
COO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, COO stands at 14.2B. In comparison, POCI has a market cap of 34.3M. Regarding current trading prices, COO is priced at $71.18, while POCI trades at $4.48.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
COO currently has a P/E ratio of 34.39, whereas POCI's P/E ratio is -4.92. In terms of profitability, COO's ROE is +0.05%, compared to POCI's ROE of -0.54%. Regarding short-term risk, COO is less volatile compared to POCI. This indicates potentially lower risk in terms of short-term price fluctuations for COO.
COO vs SDC Comparison
COO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, COO stands at 14.2B. In comparison, SDC has a market cap of 29.1M. Regarding current trading prices, COO is priced at $71.18, while SDC trades at $0.08.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
COO currently has a P/E ratio of 34.39, whereas SDC's P/E ratio is -0.03. In terms of profitability, COO's ROE is +0.05%, compared to SDC's ROE of -1.96%. Regarding short-term risk, COO is less volatile compared to SDC. This indicates potentially lower risk in terms of short-term price fluctuations for COO.
COO vs IVC Comparison
COO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, COO stands at 14.2B. In comparison, IVC has a market cap of 24.9M. Regarding current trading prices, COO is priced at $71.18, while IVC trades at $0.66.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
COO currently has a P/E ratio of 34.39, whereas IVC's P/E ratio is -0.79. In terms of profitability, COO's ROE is +0.05%, compared to IVC's ROE of -0.46%. Regarding short-term risk, COO is less volatile compared to IVC. This indicates potentially lower risk in terms of short-term price fluctuations for COO.
COO vs FEMY Comparison
COO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, COO stands at 14.2B. In comparison, FEMY has a market cap of 21.8M. Regarding current trading prices, COO is priced at $71.18, while FEMY trades at $0.80.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
COO currently has a P/E ratio of 34.39, whereas FEMY's P/E ratio is -0.88. In terms of profitability, COO's ROE is +0.05%, compared to FEMY's ROE of -3.92%. Regarding short-term risk, COO is more volatile compared to FEMY. This indicates potentially higher risk in terms of short-term price fluctuations for COO.
COO vs NXGLW Comparison
COO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, COO stands at 14.2B. In comparison, NXGLW has a market cap of 21.1M. Regarding current trading prices, COO is priced at $71.18, while NXGLW trades at $0.26.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
COO currently has a P/E ratio of 34.39, whereas NXGLW's P/E ratio is -0.19. In terms of profitability, COO's ROE is +0.05%, compared to NXGLW's ROE of -0.63%. Regarding short-term risk, COO is more volatile compared to NXGLW. This indicates potentially higher risk in terms of short-term price fluctuations for COO.
COO vs WOK Comparison
COO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, COO stands at 14.2B. In comparison, WOK has a market cap of 20.9M. Regarding current trading prices, COO is priced at $71.18, while WOK trades at $0.85.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
COO currently has a P/E ratio of 34.39, whereas WOK's P/E ratio is -3.15. In terms of profitability, COO's ROE is +0.05%, compared to WOK's ROE of -0.30%. Regarding short-term risk, COO is more volatile compared to WOK. This indicates potentially higher risk in terms of short-term price fluctuations for COO.
COO vs RVP Comparison
COO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, COO stands at 14.2B. In comparison, RVP has a market cap of 19.8M. Regarding current trading prices, COO is priced at $71.18, while RVP trades at $0.66.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
COO currently has a P/E ratio of 34.39, whereas RVP's P/E ratio is -0.87. In terms of profitability, COO's ROE is +0.05%, compared to RVP's ROE of -0.27%. Regarding short-term risk, COO is more volatile compared to RVP. This indicates potentially higher risk in terms of short-term price fluctuations for COO.
COO vs MHUA Comparison
COO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, COO stands at 14.2B. In comparison, MHUA has a market cap of 19.5M. Regarding current trading prices, COO is priced at $71.18, while MHUA trades at $0.61.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
COO currently has a P/E ratio of 34.39, whereas MHUA's P/E ratio is 1.54. In terms of profitability, COO's ROE is +0.05%, compared to MHUA's ROE of +0.09%. Regarding short-term risk, COO is less volatile compared to MHUA. This indicates potentially lower risk in terms of short-term price fluctuations for COO.
COO vs HBIO Comparison
COO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, COO stands at 14.2B. In comparison, HBIO has a market cap of 18.2M. Regarding current trading prices, COO is priced at $71.18, while HBIO trades at $0.41.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
COO currently has a P/E ratio of 34.39, whereas HBIO's P/E ratio is -0.31. In terms of profitability, COO's ROE is +0.05%, compared to HBIO's ROE of -1.10%. Regarding short-term risk, COO is less volatile compared to HBIO. This indicates potentially lower risk in terms of short-term price fluctuations for COO.
COO vs NXGL Comparison
COO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, COO stands at 14.2B. In comparison, NXGL has a market cap of 17.8M. Regarding current trading prices, COO is priced at $71.18, while NXGL trades at $2.32.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
COO currently has a P/E ratio of 34.39, whereas NXGL's P/E ratio is -5.16. In terms of profitability, COO's ROE is +0.05%, compared to NXGL's ROE of -0.63%. Regarding short-term risk, COO is more volatile compared to NXGL. This indicates potentially higher risk in terms of short-term price fluctuations for COO.
COO vs LUCYW Comparison
COO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, COO stands at 14.2B. In comparison, LUCYW has a market cap of 13.8M. Regarding current trading prices, COO is priced at $71.18, while LUCYW trades at $0.06.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
COO currently has a P/E ratio of 34.39, whereas LUCYW's P/E ratio is N/A. In terms of profitability, COO's ROE is +0.05%, compared to LUCYW's ROE of -0.95%. Regarding short-term risk, COO is less volatile compared to LUCYW. This indicates potentially lower risk in terms of short-term price fluctuations for COO.
COO vs EKSO Comparison
COO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, COO stands at 14.2B. In comparison, EKSO has a market cap of 10.1M. Regarding current trading prices, COO is priced at $71.18, while EKSO trades at $4.31.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
COO currently has a P/E ratio of 34.39, whereas EKSO's P/E ratio is -0.60. In terms of profitability, COO's ROE is +0.05%, compared to EKSO's ROE of -0.82%. Regarding short-term risk, COO is less volatile compared to EKSO. This indicates potentially lower risk in terms of short-term price fluctuations for COO.
COO vs POAI Comparison
COO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, COO stands at 14.2B. In comparison, POAI has a market cap of 8.5M. Regarding current trading prices, COO is priced at $71.18, while POAI trades at $0.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
COO currently has a P/E ratio of 34.39, whereas POAI's P/E ratio is -0.66. In terms of profitability, COO's ROE is +0.05%, compared to POAI's ROE of -5.91%. Regarding short-term risk, COO is more volatile compared to POAI. This indicates potentially higher risk in terms of short-term price fluctuations for COO.
COO vs LUCY Comparison
COO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, COO stands at 14.2B. In comparison, LUCY has a market cap of 8.2M. Regarding current trading prices, COO is priced at $71.18, while LUCY trades at $2.66.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
COO currently has a P/E ratio of 34.39, whereas LUCY's P/E ratio is 0.06. In terms of profitability, COO's ROE is +0.05%, compared to LUCY's ROE of -0.95%. Regarding short-term risk, COO is less volatile compared to LUCY. This indicates potentially lower risk in terms of short-term price fluctuations for COO.
COO vs STSS Comparison
COO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, COO stands at 14.2B. In comparison, STSS has a market cap of 5.9M. Regarding current trading prices, COO is priced at $71.18, while STSS trades at $5.79.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
COO currently has a P/E ratio of 34.39, whereas STSS's P/E ratio is N/A. In terms of profitability, COO's ROE is +0.05%, compared to STSS's ROE of -0.99%. Regarding short-term risk, COO is less volatile compared to STSS. This indicates potentially lower risk in terms of short-term price fluctuations for COO.
COO vs NSTG Comparison
COO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, COO stands at 14.2B. In comparison, NSTG has a market cap of 5.1M. Regarding current trading prices, COO is priced at $71.18, while NSTG trades at $0.11.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
COO currently has a P/E ratio of 34.39, whereas NSTG's P/E ratio is -0.03. In terms of profitability, COO's ROE is +0.05%, compared to NSTG's ROE of -1.43%. Regarding short-term risk, COO is less volatile compared to NSTG. This indicates potentially lower risk in terms of short-term price fluctuations for COO.
COO vs GCTK Comparison
COO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, COO stands at 14.2B. In comparison, GCTK has a market cap of 3.9M. Regarding current trading prices, COO is priced at $71.18, while GCTK trades at $0.14.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
COO currently has a P/E ratio of 34.39, whereas GCTK's P/E ratio is N/A. In terms of profitability, COO's ROE is +0.05%, compared to GCTK's ROE of +3.93%. Regarding short-term risk, COO is less volatile compared to GCTK. This indicates potentially lower risk in terms of short-term price fluctuations for COO.
COO vs GMVD Comparison
COO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, COO stands at 14.2B. In comparison, GMVD has a market cap of 1.8M. Regarding current trading prices, COO is priced at $71.18, while GMVD trades at $0.18.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
COO currently has a P/E ratio of 34.39, whereas GMVD's P/E ratio is -0.01. In terms of profitability, COO's ROE is +0.05%, compared to GMVD's ROE of +2.09%. Regarding short-term risk, COO is less volatile compared to GMVD. This indicates potentially lower risk in terms of short-term price fluctuations for COO.
COO vs GMVDW Comparison
COO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, COO stands at 14.2B. In comparison, GMVDW has a market cap of 1.8M. Regarding current trading prices, COO is priced at $71.18, while GMVDW trades at $7.04.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
COO currently has a P/E ratio of 34.39, whereas GMVDW's P/E ratio is N/A. In terms of profitability, COO's ROE is +0.05%, compared to GMVDW's ROE of +2.09%. Regarding short-term risk, COO is less volatile compared to GMVDW. This indicates potentially lower risk in terms of short-term price fluctuations for COO.
COO vs AVGR Comparison
COO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, COO stands at 14.2B. In comparison, AVGR has a market cap of 1.5M. Regarding current trading prices, COO is priced at $71.18, while AVGR trades at $0.47.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
COO currently has a P/E ratio of 34.39, whereas AVGR's P/E ratio is -0.05. In terms of profitability, COO's ROE is +0.05%, compared to AVGR's ROE of -54.25%. Regarding short-term risk, COO is less volatile compared to AVGR. This indicates potentially lower risk in terms of short-term price fluctuations for COO.
COO vs HRC Comparison
COO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, COO stands at 14.2B. In comparison, HRC has a market cap of 0. Regarding current trading prices, COO is priced at $71.18, while HRC trades at $155.96.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
COO currently has a P/E ratio of 34.39, whereas HRC's P/E ratio is 41.92. In terms of profitability, COO's ROE is +0.05%, compared to HRC's ROE of +0.14%. Regarding short-term risk, COO is more volatile compared to HRC. This indicates potentially higher risk in terms of short-term price fluctuations for COO.
COO vs APR Comparison
COO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, COO stands at 14.2B. In comparison, APR has a market cap of 0. Regarding current trading prices, COO is priced at $71.18, while APR trades at $37.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
COO currently has a P/E ratio of 34.39, whereas APR's P/E ratio is 22.59. In terms of profitability, COO's ROE is +0.05%, compared to APR's ROE of +9.81%. Regarding short-term risk, COO is more volatile compared to APR. This indicates potentially higher risk in terms of short-term price fluctuations for COO.
COO vs IIN Comparison
COO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, COO stands at 14.2B. In comparison, IIN has a market cap of 0. Regarding current trading prices, COO is priced at $71.18, while IIN trades at $24.23.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
COO currently has a P/E ratio of 34.39, whereas IIN's P/E ratio is 226.45. In terms of profitability, COO's ROE is +0.05%, compared to IIN's ROE of -0.00%. Regarding short-term risk, COO is more volatile compared to IIN. This indicates potentially higher risk in terms of short-term price fluctuations for COO.
COO vs ATRS Comparison
COO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, COO stands at 14.2B. In comparison, ATRS has a market cap of 0. Regarding current trading prices, COO is priced at $71.18, while ATRS trades at $5.59.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
COO currently has a P/E ratio of 34.39, whereas ATRS's P/E ratio is 14.95. In terms of profitability, COO's ROE is +0.05%, compared to ATRS's ROE of +0.31%. Regarding short-term risk, COO is more volatile compared to ATRS. This indicates potentially higher risk in terms of short-term price fluctuations for COO.
COO vs LMNX Comparison
COO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, COO stands at 14.2B. In comparison, LMNX has a market cap of 0. Regarding current trading prices, COO is priced at $71.18, while LMNX trades at $36.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
COO currently has a P/E ratio of 34.39, whereas LMNX's P/E ratio is N/A. In terms of profitability, COO's ROE is +0.05%, compared to LMNX's ROE of +0.03%. Regarding short-term risk, COO is more volatile compared to LMNX. This indicates potentially higher risk in terms of short-term price fluctuations for COO.